UBS Group
RPRX icon

UBS Group’s Royalty Pharma RPRX Stock Holding History

UBS Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,800
Closed -$1.16M – 11072
2025
Q3 		$1.16M Hold
32,800
– – ﹤0.01% 5441
2025
Q2 		$1.18M Hold
32,800
– – ﹤0.01% 5297
2025
Q1 		$1.02M Sell
32,800
-17,200
-34% -$545K ﹤0.01% 5274
2024
Q4 		$1.28M Buy
+50,000
New +$1.33M ﹤0.01% 5126
2021
Q3 		– Sell
-150,000
Closed -$6.15M – 9997
2021
Q2 		$6.15M Buy
+150,000
New +$6.38M ﹤0.01% 2474

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's RPRX Position: Q2 2026 in Review

UBS Group increased its Royalty Pharma (RPRX) stake by 73% in Q2 2026, buying an estimated $69.3M and bringing the position to 3,143,347 shares worth $176M. The position accounts for 0.02% of the portfolio, ranked #738.

UBS Group first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • UBS Group held 3,143,347 shares of Royalty Pharma worth $176M as of Q2 2026.
  • UBS Group bought 1,331,144 Royalty Pharma shares in Q2 2026, an estimated $69.3M.
  • Royalty Pharma made up 0.02% of UBS Group's portfolio in Q2 2026, its #738 holding.
  • UBS Group first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.